Autonomous Life Sciences Intelligence — HitchhikersAI
Oncology Trial Insights
Synthesised intelligence from the oncology clinical trial landscape — why anomalies matter,
competitive signals, and mechanism trends. Updated weekly from autonomous KB analysis
across trial registries and news sources.
Week of 22 May 2026 — Generated 22 May 2026, 08:00 UTC
How to read this page
Findings vs Insights: The Findings page
shows raw anomaly detection output — what happened, scored deterministically from trial
registry data. This page shows synthesised intelligence — why it matters, built by
autonomous KB analysis across news and trial signals. Each insight references one or more
confirmed trial findings as evidence.
Signal strength reflects the quality and quantity of the evidence trail
behind each insight: Strong = multiple independent sources corroborate the
signal; Moderate = single source with supporting context;
Weak = inferential with limited direct evidence. Signal strength is
not a validated accuracy measure — it is an indicator of evidence depth.